TPG buys UnitedHealth Group's Optum UK business for $1.8 billion

Transaction overview

On April 24, 2026, TPG, a prominent U.S.-based private equity firm, acquired Optum UK, a healthcare services subsidiary of UnitedHealth Group (UNH), for $1.8 billion in an all-cash transaction completed on the same day as the announcement. The deal aims to strengthen TPG's position in the UK healthcare market by integrating Optum UK’s comprehensive suite of healthcare solutions, including technology and data-driven health management services.

Deal structure and financing

TPG financed the acquisition through a combination of equity and debt, with Bank of America serving as the sole financial advisor on the buy-side. The exact split between equity and debt is not disclosed in available information. While leverage details are currently unavailable, TPG’s transaction history suggests they typically aim for conservative capital structures to minimize risk and ensure liquidity during economic downturns.

Strategic context

TPG's acquisition of Optum UK underscores its strategic focus on the rapidly evolving healthcare sector within the United Kingdom. The deal allows TPG to expand its footprint in a market characterized by growing demand for integrated health solutions, including telemedicine, digital patient engagement, and advanced analytics-driven services. For UnitedHealth Group, divesting Optum UK represents an opportunity to streamline operations and concentrate resources on core U.S.-based initiatives while retaining significant value through the sale.

Regulatory path

The acquisition of Optum UK by TPG did not face substantial regulatory hurdles, reflecting both companies’ commitment to a swift close. Given the deal’s size and cross-border nature, relevant authorities in the United Kingdom reviewed the transaction under applicable merger control regimes. To date, no major remedies or antitrust concerns have been reported, suggesting that competition regulators were satisfied with the proposed changes to market dynamics.

The deal was subject to regulatory review by the UK Competition and Markets Authority (CMA) and the European Commission due to its international scope and size. The CMA completed its Phase 1 review within a standard timeline, finding no need for further investigation or remedies based on the submitted documentation and evidence provided by both parties.